257 related articles for article (PubMed ID: 15604276)
61. EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells.
Kashuba E; Mattsson K; Pokrovskaja K; Kiss C; Protopopova M; Ehlin-Henriksson B; Klein G; Szekely L
Int J Cancer; 2003 Jul; 105(5):644-53. PubMed ID: 12740913
[TBL] [Abstract][Full Text] [Related]
62. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
[TBL] [Abstract][Full Text] [Related]
63. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4.
Marine JC; Francoz S; Maetens M; Wahl G; Toledo F; Lozano G
Cell Death Differ; 2006 Jun; 13(6):927-34. PubMed ID: 16543935
[No Abstract] [Full Text] [Related]
64. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
[TBL] [Abstract][Full Text] [Related]
65. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
Lyakhovich A; Shekhar MP
Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
[TBL] [Abstract][Full Text] [Related]
66. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis.
Mancini F; Gentiletti F; D'Angelo M; Giglio S; Nanni S; D'Angelo C; Farsetti A; Citro G; Sacchi A; Pontecorvi A; Moretti F
J Biol Chem; 2004 Feb; 279(9):8169-80. PubMed ID: 14660608
[TBL] [Abstract][Full Text] [Related]
67. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.
Coffill CR; Lee AP; Siau JW; Chee SM; Joseph TL; Tan YS; Madhumalar A; Tay BH; Brenner S; Verma CS; Ghadessy FJ; Venkatesh B; Lane DP
Genes Dev; 2016 Feb; 30(3):281-92. PubMed ID: 26798135
[TBL] [Abstract][Full Text] [Related]
68. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.
Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W
Science; 2003 Dec; 302(5652):1972-5. PubMed ID: 14671306
[TBL] [Abstract][Full Text] [Related]
69. Mdm2-mediated pRB downregulation is involved in carcinogenesis in a p53-independent manner.
Miwa S; Uchida C; Kitagawa K; Hattori T; Oda T; Sugimura H; Yasuda H; Nakamura H; Chida K; Kitagawa M
Biochem Biophys Res Commun; 2006 Feb; 340(1):54-61. PubMed ID: 16343421
[TBL] [Abstract][Full Text] [Related]
70. MDM4 binds ligands via a mechanism in which disordered regions become structured.
Sanchez MC; Renshaw JG; Davies G; Barlow PN; Vogtherr M
FEBS Lett; 2010 Jul; 584(14):3035-41. PubMed ID: 20515689
[TBL] [Abstract][Full Text] [Related]
71. G alpha 12/13 basally regulates p53 through Mdm4 expression.
Kim MS; Lee SM; Kim WD; Ki SH; Moon A; Lee CH; Kim SG
Mol Cancer Res; 2007 May; 5(5):473-84. PubMed ID: 17510313
[TBL] [Abstract][Full Text] [Related]
72. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma.
Li L; Tao Q; Jin H; van Hasselt A; Poon FF; Wang X; Zeng MS; Jia WH; Zeng YX; Chan AT; Cao Y
Clin Cancer Res; 2010 Jun; 16(11):2949-58. PubMed ID: 20395212
[TBL] [Abstract][Full Text] [Related]
73. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
74. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
75. Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review.
Teveroni E; Lucà R; Pellegrino M; Ciolli G; Pontecorvi A; Moretti F
Expert Opin Ther Pat; 2016 Dec; 26(12):1417-1429. PubMed ID: 27603098
[TBL] [Abstract][Full Text] [Related]
76. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
77. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
78. Antagonism of Myc functions by Arf.
Cleveland JL; Sherr CJ
Cancer Cell; 2004 Oct; 6(4):309-11. PubMed ID: 15488753
[TBL] [Abstract][Full Text] [Related]
79. The regulation of the p53-mediated stress response by MDM2 and MDM4.
Perry ME
Cold Spring Harb Perspect Biol; 2010 Jan; 2(1):a000968. PubMed ID: 20182601
[TBL] [Abstract][Full Text] [Related]
80. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
